Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
(BRF2023) Xi to Address Opening Ceremony of 3rd Belt and Road Forum for Int'l CooperationChinese commerce minister meets with WTO directorHainan takes lead in green auto sectorChina Energy's massive hydropower station to open in March 2024World's largest metamorphic rock oilfield found in China's Bohai SeaWhat Message Did President Xi Send During His Visit to Jiujiang?Apple reportedly cancels EV project, to focus more on AIThe 134th Canton Fair attracted overseas purchasers for new energy vehiclesTechnology adoption a key driver of greater global food productionUS users oppose possible ban on TikTok
3.0242s , 4666.9375 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,World Wonders news portal